Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration

被引：0

作者：

Lamanna, Nicole ^{[1
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

Chronic lymphocytic leukemia; relapsed after BTKi therapy; venetoclax; CHRONIC LYMPHOCYTIC-LEUKEMIA; VENETOCLAX; IBRUTINIB; OUTCOMES; ACALABRUTINIB; RESISTANCE; RITUXIMAB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EXABS-124-

引用

页码：S40 / S42

页数：3

共 50 条

[1] Frontline Treatment of Older Patient with CLL: Options and Consideration
Lamanna, Nicole
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S38 - S39
[2] Venetoclax consolidation after BTKi based therapy for patients with CLL
Heyman, Benjamin
Choi, Michael
Kipps, Thomas
[J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S67 - S68
[3] BTKi in CLL Therapy: yesterday, today and Future
不详
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 458 - 459
[4] Selecting Frontline Therapy for CLL in 2018
Jain, Nitin
[J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 242 - 247
[5] Options at the time of relapse after anti -BCMA therapy
Razzo, Beatrice
Garfall, Alfred L.
Cohen, Adam D.
[J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2023, (01) : 450 - 458
[6] Frontline Therapy of CLL: Evolving Treatment Paradigm
Boddy, Craig S.
Ma, Shuo
[J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (02) : 69 - 77
[7] Frontline Therapy of CLL—Changing Treatment Paradigms
Catherine C. Coombs
[J]. Current Hematologic Malignancy Reports, 2024, 19 : 65 - 74
[8] Survival Advantage in CLL with Frontline FCR Therapy
O'Brien, Susan
[J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 3 - 4
[9] Ibrutinib frontline in young patients with CLL
Eichhorst, Barbara
[J]. BLOOD, 2022, 140 (02) : 80 - 81
[10] Survival Advantage in CLL with Frontline FCR Therapy
Susan O’Brien
[J]. Current Hematologic Malignancy Reports, 2011, 6 : 3 - 4

← 1 2 3 4 5 →